[
  {
    "ts": null,
    "headline": "Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger",
    "summary": "Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.",
    "url": "https://finnhub.io/api/news?id=d6ae862d5e5c0c120bd48c57d94f370776bf6abba63b13b6bfaae389695ad78a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732968000,
      "headline": "Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger",
      "id": 131724710,
      "image": "",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.",
      "url": "https://finnhub.io/api/news?id=d6ae862d5e5c0c120bd48c57d94f370776bf6abba63b13b6bfaae389695ad78a"
    }
  },
  {
    "ts": null,
    "headline": "Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?",
    "summary": "The market didn't appreciate Amgen's (NASDAQ: AMGN) latest clinical data update, with the biopharma's shares falling more than 12% at one point on Nov. 26 from the previous day's close, though they recovered to close just 4.7% down for the day.  Amgen is looking to compete in the all-important market for anti-obesity medicines, facing off against the reigning champions, Eli Lilly and Novo Nordisk (NYSE: NVO).  Over the course of 52 weeks of treatment, Zepbound helps patients lose on average 24% of their mass, whereas Wegovy has been shown in clinical trials to lead to a 14% reduction in mass.",
    "url": "https://finnhub.io/api/news?id=e2e1727cd3005414c15ec595883d37e0cf92680e1f2d6a671d65d1abf2b763dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732965600,
      "headline": "Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?",
      "id": 131724711,
      "image": "https://g.foolcdn.com/editorial/images/799310/concerned-investor-with-two-people-in-background.jpg",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The market didn't appreciate Amgen's (NASDAQ: AMGN) latest clinical data update, with the biopharma's shares falling more than 12% at one point on Nov. 26 from the previous day's close, though they recovered to close just 4.7% down for the day.  Amgen is looking to compete in the all-important market for anti-obesity medicines, facing off against the reigning champions, Eli Lilly and Novo Nordisk (NYSE: NVO).  Over the course of 52 weeks of treatment, Zepbound helps patients lose on average 24% of their mass, whereas Wegovy has been shown in clinical trials to lead to a 14% reduction in mass.",
      "url": "https://finnhub.io/api/news?id=e2e1727cd3005414c15ec595883d37e0cf92680e1f2d6a671d65d1abf2b763dd"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of December 1",
    "summary": "Stay updated on dividend activity with our weekly summary for Dividend Champions, Contenders, and Challengers, including upcoming ex-dividend and pay dates.",
    "url": "https://finnhub.io/api/news?id=9642dd8f79519b81292ebdef717deaeadb802b16e54fe5f8130076cfb1bff9e6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732926885,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of December 1",
      "id": 131718114,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Stay updated on dividend activity with our weekly summary for Dividend Champions, Contenders, and Challengers, including upcoming ex-dividend and pay dates.",
      "url": "https://finnhub.io/api/news?id=9642dd8f79519b81292ebdef717deaeadb802b16e54fe5f8130076cfb1bff9e6"
    }
  }
]